Copenhagen Prospective Studies on Asthma in Childhood (COPSAC), Department of Pediatrics, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Pediatr Allergy Immunol. 2023 Nov;34(11):e14050. doi: 10.1111/pai.14050.
Blood eosinophil count is a well-established biomarker of atopic diseases in older children and adults. However, its predictive role for atopic diseases in preschool children is not well established.
To investigate the association between blood eosinophil count in children and development of atopic diseases up to age 6 years.
We investigated blood eosinophil count at age 18 months and 6 years in relation to recurrent wheeze/asthma, atopic dermatitis, allergic rhinitis, and allergic sensitization during the first 6 years of life in the two Copenhagen Prospective Studies on Asthma in Childhood cohorts (n = 1111). Blood eosinophil count was investigated in association with remission of existing atopic disease, current atopic disease, and later development of atopic disease.
Blood eosinophil count at 18 months was not associated with current wheezing/asthma or atopic dermatitis, while blood eosinophil count at age 6 years was associated with increased occurrence of current wheezing/asthma (OR = 1.1; 1.04-1.16, p = .0005), atopic dermatitis (OR = 1.06; 1.01-1.1, p = .02), and allergic rhinitis (OR = 1.11; 1.05-1.18, p = .0002). Blood eosinophil count at 18 months did not predict persistence or development of recurrent wheeze/asthma or atopic dermatitis at age 6 years.
Blood eosinophil count at 18 months was not associated with current wheezing/asthma or atopic dermatitis and did not predict persistence or development of disease. This implies a limited clinical role of blood eosinophil levels in early-life atopic disease and questions the clinical value of blood eosinophil counts measured in toddlers as a predictive biomarker for subsequent atopic disease in early childhood.
血嗜酸性粒细胞计数是一种成熟的儿童和成人特应性疾病的生物标志物。然而，其在学龄前儿童中对特应性疾病的预测作用尚未得到充分证实。
研究儿童血嗜酸性粒细胞计数与 6 岁以下特应性疾病发展之间的关系。
我们在哥本哈根儿童哮喘前瞻性研究的两个队列（n=1111）中，调查了 18 个月和 6 岁时的血嗜酸性粒细胞计数与 6 岁前反复喘息/哮喘、特应性皮炎、过敏性鼻炎和过敏致敏的关系。我们研究了血嗜酸性粒细胞计数与现有特应性疾病的缓解、当前特应性疾病以及以后特应性疾病的发展之间的关系。
18 个月时的血嗜酸性粒细胞计数与当前喘息/哮喘或特应性皮炎无关，而 6 岁时的血嗜酸性粒细胞计数与当前喘息/哮喘（OR=1.1；1.04-1.16，p=0.0005）、特应性皮炎（OR=1.06；1.01-1.1，p=0.02）和过敏性鼻炎（OR=1.11；1.05-1.18，p=0.0002）的发生率增加相关。18 个月时的血嗜酸性粒细胞计数不能预测 6 岁时反复喘息/哮喘或特应性皮炎的持续或发展。
18 个月时的血嗜酸性粒细胞计数与当前喘息/哮喘或特应性皮炎无关，也不能预测疾病的持续或发展。这意味着血嗜酸性粒细胞水平在生命早期特应性疾病中的临床作用有限，并对在幼儿中测量血嗜酸性粒细胞计数作为预测早期儿童特应性疾病的生物标志物的临床价值提出了质疑。
